Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915589 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bayer